Insights

Strategic Acquisition Fuel Seamless Therapeutics recently became the focus of a high-value acquisition by Eli Lilly for $1.12B in January 2026, signaling strong strategic interest in recombinase-based gene editing and hearing loss programs. This indicates a favorable market appetite for partnerships or licensing deals with large pharma looking to augment gene editing capabilities.

Collaborations Velocity Multiple global collaborations and licensing agreements with Lilly and a German partner in 2026 show a rapid, deal-ready posture. This creates opportunities for co-development, licensing, or expansion of existing collaborations into additional indications or geographies.

Hearing Loss Focus A clear emphasis on developing programmable recombinase-based therapeutics for hearing loss aligns with an underserved or strategically attractive market segment. Targeted outreach to audiology/hearing care stakeholders, contract research organizations, and payer landscape analyses could unlock focused partnerships.

Programmatic Platform The core technology platform enabling recombinase reprogramming offers a broad pipeline potential across indications. This suggests opportunities for partnerships around platform licensing, joint ventures, or milestone-driven collaborations to de-risk and accelerate pipeline expansion.

Startup to Growth Trajectory Seamless Therapeutics operates with a lean team yet has significant investor and partner interest, evidenced by seed funding totals and large-scale collaborations. This indicates readiness for scalable BD activities such as strategic co-development deals, milestone-based funding, and expedited clinical collaboration discussions.

Similar companies to Seamless Therapeutics

Seamless Therapeutics Tech Stack

Seamless Therapeutics uses 8 technology products and services including RSS, WordPress, CookieYes, and more. Explore Seamless Therapeutics's tech stack below.

  • RSS
    Content Management System
  • Content Management System
  • Cookie Compliance
  • UNIX
    Operating Systems
  • Platform As A Service
  • Security
  • Team Collaboration
  • Google Search Console
    Web Analytics

Media & News

Seamless Therapeutics's Email Address Formats

Seamless Therapeutics uses at least 2 email formats:
Seamless Therapeutics Email FormatsExamplePercentage
First.Last@seamlesstx.comJohn.Doe@seamlesstx.com
94%
FL@seamlesstx.comJD@seamlesstx.com
6%

Frequently Asked Questions

What is Seamless Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Seamless Therapeutics's official website is seamlesstx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Seamless Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Seamless Therapeutics's annual revenue is estimated to be $10M - $25M.

What is Seamless Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Seamless Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Seamless Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Seamless Therapeutics has approximately 31 employees across 3 continents, including Europe, North America and Asia. Key team members include Chief Technology Officer: F. L., Head Of Operations, Managing Director And Co-Founder: A. H. and Head Of Cellular Assays: M. Z. Explore Seamless Therapeutics's employee directory with LeadIQ.

What industry does Seamless Therapeutics belong to?

Minus sign iconPlus sign icon
Seamless Therapeutics operates in the Biotechnology Research industry.

What technology does Seamless Therapeutics use?

Minus sign iconPlus sign icon
Seamless Therapeutics's tech stack includes RSS, WordPress, CookieYes, UNIX, WP Engine, 1Password, Box and Google Search Console.

What is Seamless Therapeutics's email format?

Minus sign iconPlus sign icon
Seamless Therapeutics's email format typically follows the pattern of First.Last@seamlesstx.com. Find more Seamless Therapeutics email formats with LeadIQ.

How much funding has Seamless Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Seamless Therapeutics has raised $25M in funding. The last funding round occurred on Apr 23, 2024 for $13M.

When was Seamless Therapeutics founded?

Minus sign iconPlus sign icon
Seamless Therapeutics was founded in 2022.
Seamless Therapeutics logo

Seamless Therapeutics

Biotechnology ResearchSaxony, Germany11-50 Employees

Seamless Therapeutics is a small biotechnology company based in Dresden, Germany, pursuing advances in gene editing through a platform designed to reprogram recombinases, a versatile class of enzymes. The objective is to restore health in patients with severe conditions using this approach with emphasis on safety and precision. It is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

The company engages in collaborations and partnerships to advance its programs, including efforts related to hearing-loss therapies. In early 2026, reports indicate a global research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss. The organization operates with a relatively small team in Dresden.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2022
Employees
11-50

Section iconFunding & Financials

  • $25M

    Seamless Therapeutics has raised a total of $25M of funding over 3 rounds. Their latest funding round was raised on Apr 23, 2024 in the amount of $13M as a Seed.

  • $10M - $25M

    Seamless Therapeutics's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.